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Because of subtle differences between mouse and
human skin, mice have traditionally not been an
ideal model to study melanoma development.
Understanding of the molecular mechanisms of
melanoma predisposition, however, has been greatly
improved by modeling various pathway defects in
the mouse. This review analyzes the latest develop-
ments in mouse models of melanoma, and sum-
marizes what these may indicate about the
development of this neoplasm in humans. Mutations
of genes involved in human melanoma have been
recapitulated with some unexpected results, particu-
larly with respect to the role of the two transcripts
(Ink4a and Arf) encoded by the Cdkn2a locus. Both
the Ink4a/pRb and Arf/p53 pathways are involved in
melanoma development in mice, and possible mech-
anisms of cross-talk between the two pathways are
discussed. We also know from mouse models that
Ras/mitogen-activated protein kinase pathway acti-
vation is very important in melanoma development,
either through direct activation of Ras (e.g., Hras
G12V), or via activation of Ras-effector pathways by
other oncogenes (e.g., Ret, Hgf/Sf). Ras can co-
operate with the Arf/p53 pathway, and probably the
Ink4a/Rb pathway, to induce melanoma. These
three growth regulation pathways (Ink4a/pRb, Arf/
p53, and Ras/mitogen-activated protein kinase)
seem to represent three major ``axes'' of melanoma
development in mice. Finally, we summarize experi-
ments using genetically modi®ed mice that have
given indications of the intensity and timing of ultra-
violet radiation exposure that may be most respon-
sible for melanoma development. Key words: knockout
mice/melanoma/transgenic mice. J Invest Dermatol
119:783±792, 2002
H
istorically, the mouse has not been a good model for
studying melanoma. Advances in methodologies to
generate transgenic and knockout animals, how-
ever, have enabled researchers to assess the in vivo
effects of pathways thought to be dysregulated in
human melanoma development. Furthermore, new experimental
ultraviolet radiation (UVR) treatment regimens have shed some
light on the environmental events thought to contribute to the
genesis of this neoplasm.
Melanoma is a tumor of pigment-producing cells (melanocytes)
that differentiate from neural crest progenitor cells during embry-
onic development. Melanocytes are located in the skin, hair
follicles, stria vascularis of the inner ear, and uveal tract of the eye.
Ocular (uveal) melanomas arise from neural crest derived
melanocytes within the eye. The only pigment cells not arising
from neural crest precursors are those of the retinal pigment
epithelium (RPE), which are derived from epithelial cells in the
optic cup. During embryonic development neural crest cells
differentiate within the embryo through two major pathways: (i)
the ``ventral'' pathway, which gives rise to neurons and glial cells of
the peripheral nervous system, and (ii) the ``dorsolateral'' pathway
from which pigment cells arise. Pigment cell precursors (melano-
blasts) migrate ®rst to the dermis and differentiate (possibly under
the in¯uence of a-melanocyte-stimulating hormone and other
factors), then to the epidermis (Quevedo and Fleischmann, 1980).
In contrast to humans, in which there is a strong association
between UV exposure and melanoma development (Whiteman et
al, 2001), normal adult mice do not develop melanomas, even after
chronic exposure to UVR. Traditionally, shaved or hairless mice
have been exposed to various acute (intense, short-term) and
chronic (low level, long-term) UV treatments to simulate human
sun exposure. These treatments promote various types of skin
cancers, including squamous cell carcinoma, papilloma, and
®brosarcoma, but not melanoma (Gallagher et al, 1984). Even
cotreatment with carcinogens such as 7,12-dimethylbenz[a]anthra-
cene (DMBA) promote little or no melanoma development,
although there is a signi®cant increase in the frequency of the other
skin cancers. The architecture of mouse and human skin shows
some subtle differences, and it is thought that differences in
melanocyte structure and location within the skin may be
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responsible for the inability to induce melanomas in mice with
UVR. Epidermal melanocyte numbers increase substantially after
birth for about 2 wk; however, in mouse skin, but not human skin,
nonfollicular melanocyte numbers decline as they follow the
basement membrane in the invagination process involved in the
formation of hair follicles (Hirobe, 1995). Thus in adult mice most
melanocytes are located in hair follicles (Hirobe, 1995), although
some are still located in the epidermis, particularly in nonhairy skin
(e.g., ears, footpads). It is thought that due to their location,
follicular melanocytes may be more protected from UVR, although
this has not been proven.
A number of genetic abnormalities involved in human mela-
noma susceptibility and tumor progression have been recapitulated
in mice. The purpose of this review is to outline the latest
developments in mouse models of melanoma, and to summarize
what these may indicate about the development of this neoplasm in
humans. To begin, genes known to be involved in the develop-
ment of human melanoma will be discussed, followed by a
summary of each of the mouse models of melanoma generated to
date. Lastly, the role of UVR in melanoma genesis in these animals
will be critically assessed.
GENES AND PATHWAYS INVOLVED IN HUMAN
MELANOMA DEVELOPMENT
The hallmark of solid tumor development is the acquisition of
multiple genetic defects involving the inactivation of tumor
suppressor genes (TSG) and the activation of oncogenes. In
cutaneous melanoma, nonrandom deletions and rearrangements are
seen in several chromosomal regions, including 1p, 7q, 9p, 10q, and
11q (Dracopoli and Fountain, 1996). At present, the two most
important TSG involved in human melanoma are CDKN2A and
PTEN, mapping to 9p and 10q, respectively. Potential oncogenes
include CDK4, NRAS, and epidermal growth factor receptor
(EGFR), and various protein tyrosine kinases (PTK), such as EPH-
A2 and EPH-B3, that are overexpressed in up to 90% of melanoma
cell lines (reviewed in Easty and Bennett, 2000). Interestingly,
other PTKs, such as KIT and FES, are consistently downregulated
in melanoma cell lines (Easty and Bennett, 2000).
CDKN2A, mapping to a frequently deleted region of 9p21,
encodes p16INK4A (hereafter termed INK4A), a cyclin-dependent
kinase (CDK) inhibitor that binds to and inhibits CDK4 and
CDK6. When complexed with D-type cyclins these kinases drive
entry into the cell cycle by phosphorylating the retinoblastoma
family of proteins (pRb), which causes the release of E2F
transcription factors and expression of E2F-regulated genes, thereby
allowing progression from G1 to S phase. CDKN2A can be
inactivated by several mechanisms, homozygous deletion, mutation
or promoter methylation. Such alterations are frequently detected
somatically in sporadic melanomas (e.g., Dracopoli and Fountain,
1996; Pollock and Trent, 2000), and constitutionally in familial
melanoma patients (e.g., Hussussian et al, 1994; Kamb et al, 1994).
Loss of INK4A function partially inactivates the G1 block, and also
leads to escape from cell senescence in culture.
Further evidence implicating the INK4A/cyclin D/CDK4/pRb
pathway comes from the ®nding of two rare germline CDK4
mutations in melanoma kindreds (Zuo et al, 1996; Sou®r et al,
1998). Both mutations (R24C and R24H) prevent CDK4 from
being inhibited by INK4A, underlining the importance of CDK4
as a second melanoma susceptibility gene. CDK4 can act as an
oncogene in some tumors (mainly melanomas and gliomas) where
its somatic overexpression usually results from gene ampli®cation
(He et al, 1994; Schmidt et al, 1994). To date, activating mutations
of CDK4 (e.g., R24C) have only been detected somatically in
melanoma (e.g., Tsao et al, 1998). Mutations that affect the activity
of any component of the INK4A/CDK4/cyclin D/pRb pathway
have important rami®cations for melanocyte transformation.
Nearly all melanomas have been found to have a defect in this
pathway (Castellano et al, 1997; Walker et al, 1998).
In a situation so far unique in the human and mouse genomes,
CDKN2A also encodes a distinct and otherwise unrelated tumor
suppressor protein, p14ARF (p19Arf in mouse; hereafter termed
ARF), which acts through a different pathway involving stabiliza-
tion of p53 through abrogation of HDM2 (Mdm2 in mouse)-
induced p53 degradation (Zhang et al, 1998). The alternatively
spliced INK4A and ARF mRNA are transcribed off different ®rst
exons, and utilize the same second exon, but in a different reading
frame (Fig 1). CDKN2A germline mutations in exon 1a affect
only the INK4A transcript, whereas some of those occurring in
exon 2 can affect both INK4A and ARF. Evidence is mounting
that germline deletion (Bahuau et al, 1998; Petronzelli et al, 2001;
Randerson-Moor et al, 2001) or mutation (Rizos et al, 2001) of
exon 1b may also predispose to melanoma as well as tumors of the
neural system. Somatic exon 1b mutations have not been detected
in uncultured melanomas, although melanoma cell lines have been
reported with speci®c deletions of exon 1b, leaving INK4A intact
(Kumar et al, 1998).
Regulation of the G1±S phase cell cycle transition is made more
complex by the existence of other CDK4 inhibitors, including the
INK4-speci®c inhibitors p15INK4B, p18INK4C, and p19INK4D, and
the less speci®c CIP1/KIP1 inhibitors p21CIP1, p27KIP1, and
p57KIP2, which bind many CDKs (Fig 2). The latter can bind to,
but do not inhibit CDK4. To proceed fully through G1, complete
phosphorylation and inactivation of pRb may require the kinase
activity of both CDK4 and CDK2, made possible in part by
reassortment of inhibitors, particularly p27KIP1 shuf¯ing between
cyclin D/CDK4 and cyclin E/CDK2 complexes, leading to
activation of the latter (reviewed in Sherr and Roberts, 1999). In
effect, CDK4 can also help promote G1±S phase progression by
titrating p27KIP1 away from CDK2/cyclin E complexes. CDKN2A
is the only CDK-inhibitor gene mutated in human melanoma, and
none of the knockout mouse models of the other inhibitors
develop skin cancers, although some are susceptible to the
development of other tumor types, particularly of neuroendocrine
origin (reviewed in Chin et al, 1998).
Cytogenetic deletions and loss of heterozygosity on chromosome
10q is a common feature of human melanoma. A candidate tumor
suppressor, PTEN, was isolated from 10q23, and subsequently
shown to be mutated or deleted in many tumor types (reviewed in
Cantley and Neel, 1999). Germline PTEN mutations have been
detected in several familial hamartoma syndromes, including
Cowden disease and Bannayan±Riley±Ruvulcaba syndrome (re-
viewed in DiLiberti, 1998). In the largest study of PTEN in
melanoma carried out to date (Pollock et al, 2002), deletion or
mutation of the gene was detected in 23% of melanoma cell lines,
which, in terms of mutation frequency, makes it possibly the most
important ``classical'' TSG gene in melanoma after CDKN2A
(although downregulation by mechanisms other than mutation or
Figure 1. Genomic organization, alternative splicing and
products of the Cdkn2a locus conserved between mouse and
human. E1b is exon 1b, E1a, exon 1a, E2 is exon 2, and E3 is exon
3. Both transcripts share the second and third exons but not the ®rst.
The Ink4a transcript uses exon 1a, whereas the Arf transcript uses exon
1b. The unshaded portions of each exon correspond to the untranslated
regions of the transcripts.
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deletion may be more common for some PTK, e.g., KIT and FES).
PTEN functions by dephosphorylating the lipid second messenger
phosphotidylinositol (PI) 3,4,5 triphosphate and other proteins in
the cascade that controls aspects of cell growth and survival,
including apoptosis (reviewed in Maehama and Dixon, 1999). One
of the major PTEN pathways involves Ras, PI3K, and AKT (PKB).
Uncontrolled activity of any of these proteins is oncogenic. Because
PTEN and NRAS mutations seem to be mutually exclusive in
human melanoma, it is thought that they may act through the same
pathway (Tsao et al, 2000). This is supported by functional evidence
showing that PTEN is also capable of suppressing activated Ras-
mediated transformation of NIH3T3 cells (Tolkacheva and Chan,
2000; Tsao et al, 2000), associated with suppression of the PI3K
signaling cascade stimulated by Ras. Thus the activation of Ras and
loss of PTEN may be substantially equivalent, at least in terms of
their actions through the PI3K pathway. PTEN has also been
shown to induce cell cycle arrest mediated by PI3K in a pRb-
dependent manner (Paramio et al, 1999), possibly by down-
regulating cyclin D and upregulating p27Kip1 (Atkas et al, 1997;
Weng et al, 2001).
Activating mutations of the Ras family (in general Nras, but to a
lesser extent Hras and Kras) are detected in about 15% of
melanocytic lesions (van Elsas et al, 1996), but appear to be a late
event in melanoma progression. Although the genetic evidence
outlined above points to a role for the Ras/PI3K/Akt pathway in
melanoma, Ras has multiple effectors (reviewed in Hunter, 1997;
Sears and Nevins, 2002) that may also stimulate other pathways
involved in melanoma development. These may include the Ras/
Raf/mitogen-activated protein kinase (MAPK) pathway that
promotes transcription of CCND1 (the gene encoding cyclin
D1), and also assists in post-translational assembly of cyclin D/
CDK4 complexes. Stimulation of CCND1 transcription is also
mediated by activation of another Ras effector, RalGDS.
Furthermore, Ras stimulation through the RhoA GTPase pathway
can induce degradation of p27KIP1 (Hu et al, 1999), thus releasing
inhibition of cyclin E/CDK2 activity needed for cells to proceed
into S-phase. Ras effectors are capable of inducing senescence,
apoptosis, or activating cell proliferation, with the various effector
pathways collaborating to achieve speci®city of signaling dependent
on the setting (Sears and Nevins, 2002).
GENETICALLY MODIFIED MOUSE MODELS TO STUDY
MELANOMA DEVELOPMENT
Attempts to induce transformation of melanocytes in mice have, in
general, utilized transgenic methods to overexpress oncogenes
(Table I), and homologous recombination techniques to ``knock
out'' portions of TSG or ``knock in'' mutations of either of TSG or
oncogenes (Table II).
TRANSGENIC MODELS
Tyr-SV40E Among the ®rst genetically modi®ed mice reported
to develop melanoma were those generated by Mintz and co-
workers. These transgenic animals, termed Tyr-SV40E,
overexpressed SV40 T antigen (Tag) under the control of the
melanocyte-speci®c tyrosinase (Tyr) gene promoter, and were
susceptible to melanoma (Table I), developing mainly ocular
melanomas (OMM) at an early age (Bradl et al, 1991; Klein-Szanto
et al, 1991). The tumors grew rapidly and metastasized to other
parts of the body. Melanoma development was greatly dependent
on copy number of the transgene. Low copy number animals were
used to study cutaneous melanomas (CMM), as the high expresser
mice died very early from OMM, which developed mainly in the
RPE. The CMM arose more frequently from hair follicle
melanocytes than those in the epidermis (Silvers and Mintz,
1998). SV40 Tag disrupts various cellular pathways, but
signi®cantly, one of the ways it causes cellular transformation is
by inactivating both pRb and p53 (reviewed in Ali and DeCaprio,
2001).
Figure 2. Cyclin-dependent kinase inhibitors capable of binding to Cdk4. To completely proceed through G1, successive phosphorylation of
pRb by both Cdk2 and Cdk4 may be required.
VOL. 119, NO. 4 OCTOBER 2002 MOUSE MODELS OF MELANOMA 785
Some of the most interesting ®ndings to come from the Tyr-
SV40E overexpresser animals were those from grafting experiments
to analyze the contribution of age and skin from different regions of
the body to the development and latency of CMM (Mintz and
Silvers, 1993). Donor skin excised from different body sites on high
copy number transgenic mice were grafted on to less melanoma
susceptible, longer-living, low copy number transgenic animals of
various ages. Grafts on to neonates resulted in CMM development
with much shorter latency than those on to adult animals. This
observation probably stems from the large number of incompletely
differentiated, growth factor-receptive melanocytes in neonatal
skin, or extrinsic factors from surrounding keratinocytes that may
stimulate melanocyte cell division. These hypotheses are supported
by the observation that CMM on grafts from body skin always
appeared near the edge of the grafts, presumably stimulated by
in¯ammatory and wound-healing cytokines and other factors.
Furthermore, grafts of snout skin on to low copy number
transgenic hosts resulted in multiple lesions at the graft site,
compared with single lesions at the sites of grafts taken from dorsal
skin. Thus, the surrounding microenvironment, as well as the state
of initiation of the melanocytes themselves, contributes to CMM
development.
Tyrosinase-related protein 1 (Tyrp1) SV40 Tag The Tyrp1
gene promoter has also been used to overexpress SV40 Tag in mice
(Penna et al, 1998). In this case overexpression was generally
restricted to the RPE of the eye, whereas expression in melanocytes
of the skin was very low. Pigmented tumors developed in the RPE
of these animals and metastasized to lymph nodes and the spleen in as
little as 3 mo (for a review of transgenic models of melanoma of the
skin and RPE see Beermann et al, 1999).
Metallothionein (Mt1)-Ret and Tyrp1-Ret In transgenic mice
overexpressing the Ret proto-oncogene, driven by an inducible
Mt1 gene promoter (Iwamoto et al, 1991; Takahashi et al, 1992;
Kato et al, 1998), melanocytes proliferated and underwent
neoplastic transformation. The tumors arose from cutaneous
melanocytes, and also from the choroidal neural crest-derived
pigment cells within the eye. Unlike some of the Tyr-SV40E
melanomas, those in the Mt1-Ret lines did not metastasize. In a
similar study, when Ret was overexpressed in the RPE using the
Tyrp1 gene promoter (Schmidt et al, 1999), the animals developed
microphthalmia (small eyes), with thickened RPE and benign
tumors of the RPE observed in some animals. RET, CDK4, and
MET are at present the only three cases of an oncogene being
responsible for susceptibility to cancer in humans. RET mutations
predispose to multiple endocrine neoplasia type 2 (Mulligan et al,
1993). RET is a cell surface receptor tyrosine kinase (RTK). It is
involved in differentiation and proliferation of neural crest cells as
the receptor for glial cell line-derived neurotrophic factor. Ret
functions through a variety of signaling pathways, including the
Ras and PI3K cascades (reviewed in Van Weering and Bos, 1998).
RTK are also implicated in melanoma development in the
Xiphophorus ®sh model, where the role of Xmrk (an EGFR
homolog) has been well established (reviewed in Wellbrock et al,
1997). EGF also acts through the Ras/Raf/MAPK pathway, and
human EGFR maps to chromosome 7p11±13, a region commonly
ampli®ed in melanoma. The effect of Ret in eye development in
the transgenic animals may be partly mediated by the effect of the
Ret/RTK/MAPK pathway on increasing the activity of the
microphthalmia transcription factor (Hemesath et al, 1998).
Mt1-hepatocyte growth factor/scatter factor (Mt1-Hgf/
Sf) The metallothionein gene promoter was also utilized in
another mouse model to drive overexpression of Hgf/Sf (Otsuka et
al, 1998). These mice developed melanocyte dysplasia and
metastatic melanoma. HGF/SF is a multifunctional cytokine,
which mediates proliferation partly by stimulating p38MAPK
Table I. Transgenic mouse models of melanoma
Genetic
modi®cation
(promoter/gene) Strain
Spontaneous
melanoma Tumor type
UV-induced
melanomasa UV wavelengths UV protocol Reference
Tyr-SV40 Tag
(high expresser)
C57/BL6 Yes, up to 100%
from 4 wk
Predominantly
OMM, but some
CMM, metastatic
Mortality too high
to be assessed
Bradl et al (1991)
Klein-Szanto et al (1991)
Tyr-SV40 Tag
(low expresser)
C57/BL6 Infrequent OMM,
no CMM
26%CMM;
latency
37±98 wk
70% UVB
280±320nm;
29.7% UVA,
320±380 nm
3.28 kJ per m2 to
4 d old neonates,
repeated for 5 d
Klein-Szanto et al (1994)
Kelsall and Mintz (1998)
Tyrp1-
SV40 Tag
NMRI/HAN Yes, 100%
OMM by 3 mo
Metastatic
RPE tumours
Not assessed Penna et al (1998)
Mt1-Ret BALB/C,
C57BL6
Yes, up to 93%
OMM by 5 mo
CMM and OMM,
not metastatic
Increased
invasiveness of
tumors
Broad-spectrum:
250±400 nm
(60% UVB)
Incremental
2.25±6 kJ per m2
tri-weekly for
34 wk
Iwamato et al (1991)
Kato et al (2000)
Tyrp1-Ret NMRI Yes, OMM Not assessed Not assessed Schmidt et al (1999)
Tyr-Hras (G12V) C3H 12% OMM,
no CMM
Melanocyte
hyperplasia
20% naevi and
CMM, only on
albino
background
90% UVB
280±340 nm
Bi-weekly for
38 wk 5.6±8.06
kJ per m2
Broome-Powell et al
(1995, 1999)
Tyr-Hras (G12V) mixed Very rarely Melanocyte
hyperplasia
Not assessed Chin et al (1997)
Mt1-Hgf/Sf FVB Yes, 22%, mean
age of onset
15.6 mo
Melanocyte
hyperplasia,
CMM,
metastatic
No increase
in CMM
240±400 nm 2.25±6 kJ per m2
tri-weekly for
17 wk
Otsuka et al (1998)
Noonan et al (2000)
Mt1-Hgf/Sf FVB As above As above CMM in 80%
within 12 mo
240±400 nm 9.2 kJ per m2,
1 dose to 4 d
old neonates
Noonan et al (2001)
Krt4-Scf C57BL No Epidermal
melanocytosis
Not assessed Kunisada et al (1998)
a% of mice with UV-induced melanomas; see Table III for summary of UV exposure protocols.
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activity and upregulating CCND1 transcription (Recio and
Merlino, 2002). It also affects motility and movement of a wide
variety of epithelial cells expressing its RTK, MET. Constitutively
active MET has also been implicated in oncogenesis in humans,
with some families with hereditary papillary renal carcinoma
carrying mis-sense mutations in its tyrosine kinase domain (Schmidt
et al, 1997). Moreover, MET is inappropriately expressed in a range
of tumors such as melanoma, rhabdomyosarcoma, hepatoma, and
mammary carcinoma. In the Mt-Hgf/Sf transgenic mice,
melanocytes were overabundant in the epidermis, particularly at
the dermal±epidermal junction, and concentrated in nonhairy parts
of the body, including the paws, tail, ears, and muzzle. CMM
developed in 22% of animals, and 21% of these tumors
metastasized. The hyperproliferation of melanocytes concentrated
them in locations away from the hair follicles, in the epidermis and
basal layer, the location of melanocytes in human skin. The CMM
that developed in these mice were of dermal origin, however,
unlike most human CMM, which are usually of epidermal origin.
The dramatic effect on melanocytes in both Mt-Hgf/Sf and Mt-Ret
animals seems at odds with the fact that the Mt1 gene promoter
seems to be functional in virtually all tissue types, with high levels
observed in various tissues, including the skin (Takayama et al,
1996).
Keratin K4-stem cell factor Mice transgenic for stem cell
factor (Scf) driven by the keratin K4 gene (Krt4) promoter Krt4-Scf
also develop melanocyte dysplasia (melanocytosis) (Kunisada et al,
1998). SCF is the ligand for the Kit RTK that regulates the
migration and development of primordial germ cells,
hematopoietic stem cells, melanocytes, and mast cells (Kunisada et
al, 1998; Lyman and Jacobsen, 1998). Interestingly, the location of
melanocytes in the skin of adult transgenic animals closely
resembles that of human skin, in that melanocytes tend to stay
within the epidermis, instead of congregating around hair follicles
as in wild-type mice. SCF has this effect on melanocytes via
stimulation of the Kit receptor, which in turn can activate the
MAPK pathway (Hemesath et al, 1998). Furthermore, as Scf
expression is limited to keratinocytes, this mouse model shows that
signals from surrounding keratinocytes can dramatically affect
melanocyte localization during development. Although these mice
do not develop melanoma, they appear to be a useful mouse model
for melanocyte localization that mimics human skin.
Tyr-Hras (G12V) Utilizing slightly different versions of the
melanocyte-speci®c tyrosinase gene promoter/enhancer sequences,
two groups have generated transgenic mice overexpressing
oncogenic Hras (G12V). Broome Powell et al (1995) used a
2.5 kb fragment containing the tyrosinase promoter and some
regulatory elements, whereas Chin et al (1997) used a chimeric
5.5 kb fragment containing the same tyrosinase gene promoter but
slightly different upstream enhancer sequences (Ganss et al, 1994).
The ®rst reported Tyr-Hras transgenics (Broome Powell et al, 1995)
were signi®cantly smaller than their wild-type littermates, and
displayed hyperpigmentation of the snout, feet, and tail. The
transgenic animals were blind and consistently moved in a circling
or twirling motion, probably caused by severe abnormalities within
the inner ear. Although these mice only very rarely developed
CMM, melanocyte hyperplasia, or melanocytosis was often
observed in the dermal and epidermal layers of the skin, inner
ear, and parts of the brain. Some of the nonmelanocyte
Table II. Knockout/knockin mouse models of melanoma
Genetic modi®cation
Spontaneous
melanomasa
Induced
melanomas
Spontaneous tumors
(nonmelanoma)b
Induced tumors
(nonmelanoma)b
MEF/cultured
tumor cells Reference
Ink4a±/±:Arf±/±, del
Cdkn2a exons 2
and 3
None None 69% at average of
29 wk, FS, L, S
90% at 20 wk with
DMBA/UVB;c FS,
L, SSC
Immortal and
transformedby
activated Hras
Serrano et al (1996)
Arf±/±, del exon 1b None None 33% at 24 wk;
FS, L, SSC, G,
S, A
82% at 20 wk with
DMBA; SCC, L, S
Immortal and
transformedby
activated Hras
Kamijo et al (1997)
Ink4a*/*, ``knockin
G101 stop mutation''
None Very rare with
DMBA, but
limited numbers
17% by 17 mo; L No assessment with
DMBA due to limited
numbers
Undergo senescence,
not transformed by
activated Hras
Krimpenfort
et al (2001)
Ink4a±/±, del exon 1a 2.5% of animals 7% with
DMBA
26% by 58 wk; S, L 50% at 23 wk with
DMBA; L, A, S
Undergo senescence,
not transformed by
activated Hras
Sharpless
et al (2001)
Ink4a±/±:Arf±/±:Tyr-
Hras (G12V)
60% at 6 mo As for Ink4a±/±/Arf±/±
animals
In vitro melanoma
cell growth
suppressed
by Ink4a
Chin et al (1997)
Ink4a±/±:Arf+/± 8% by 17 mo 50% by 9 mo
with DMBA
100% by 17 mo;
FS, L, S, A, SCC
P, A, others Krimpenfort
et al (2001)
p53 ±/±:Tyr-Hras
(G12V)
29% by 17 wk
et al (2001)
74% death or
nonmelanoma tumors
by 17 wk; S, L
In vitro melanoma
cell growth not
suppressed by Ink4a
Bardeesy
Pten±/±:Ink4a±/±:
Arf±/±
7% by 31 wk 100% beginning at
week 7; L, E, S
Increased growth and
susceptibility to Hras
transformation
You et al (2002)
Cdk4R24C/R24C
``knockin'' mutation
None 70% by 20 wk
with
DMBA + TPA
93% by 14±16 mo;
S, E, A, L
­ severity P, S and
15% SCC, with
DMBA, TPA
Weakly transformed
by activated Hras
Sotillo et al
(2001a, >b)
Cdk4±/± None None (diabetes) Rane et al (1999)
Integration into
unknown locus
100% CMM by
12 mo
None Chen et al (1996)
Zhu et al (1998)
aPercentage of mice that developed CMM. Blank ®eld = not assessed.
bOverall percentage of animals with nonmelanoma tumors, with most common tumor types listed for each model: FS, ®brosarcoma; S, other sarcoma; P, papilloma; L,
lymphoma; A, adenoma; G, glioma; SCC: squamous cell carcinoma; E, endocrine tumors.
cWavelengths used, 295±310 nm (UVB); 27 exposures 1±7 kJ per m2 beginning at postnatal days 4±8; strain, C57BL/6.
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abnormalities seen in these animals are due to tyrosinase gene
promoter activity that can be detected in parts of the nervous
system and other neural crest-derived cells (Klein-Szanto et al,
1991). Three transgenic lines of similar Tyr-Hras transgenics were
generated in the laboratory of Chin et al (1997). The highest copy
number overexpresser had a very compromised phenotype similar
to that described by Broome Powell et al (1995), but the animals
died at a young age and the line was not continued. The other two
lines were overtly normal, although the occasional animal
developed OMM (Chin et al, 1997). As with other transgenic
models discussed above, activated Ras transgene overexpression
probably stimulates signaling through the RTK/Ras/Raf/MAPK
pathway, or a related signaling cascade that controls proliferation as
well as cell±cell communication and cell positioning with the skin.
Thus, these transgenic models also have in common the re-
localization and proliferation of melanocytes to produce
hyperpigmentation of nonhairy skin.
GENE KNOCKOUT AND KNOCKIN MOUSE MODELS
OF MELANOMA
Cdkn2a knockouts The ®rst reported Cdkn2a knockout mice
were generated using homologous recombination techniques to
ablate exon 2, which inactivated both the Ink4a and Arf transcripts
(Serrano et al, 1996). These animals did not develop melanoma,
although they were susceptible to the development of other
tumors, particularly ®brosarcomas and lymphomas (Table II).
These tumors increased in frequency after treatment with the
carcinogen DMBA. Melanocytes cultured from these animals fail to
senesce, and have decreased pigmentation levels associated with the
loss of senescence (Sviderskaya et al, 2002). Furthermore, Ink4a±/±:
Arf±/± murine embryonic ®broblasts (MEF) proliferated rapidly,
grew in colonies, and could be transformed with activated Hras.
The MEFs could also be transformed with equal ef®ciency by
activated Raf, implicating the Ras/Raf/MAPK pathway (Serrano et
al, 1996). To assess the effects of deleting the Arf transcript alone,
exon 1b of the Cdkn2a locus was ablated in mice (Kamijo et al,
1997). The animals had a very similar phenotype to the
Ink4a±/±:Arf±/± mice, implying that inactivation of Arf, rather
than Ink4a, may be responsible for the tumor susceptibility
phenotype in the initial model.
Following on from the ®nding that Ink4a±/±:Arf±/± MEF were
susceptible to activated Hras transformation, Chin et al (1997)
crossed Ink4a±/±:Arf±/± mice with Tyr-Hras transgenic mice. The
resulting progeny developed CMM spontaneously with a high
penetrance. OMM also occurred, but were less frequent. These
data indicate that a further genetic ``hit'' in addition to Cdkn2a
inactivation is also needed for melanocyte tumorigenesis; however,
the melanomas were only locally invasive and did not metastasize,
suggesting that still further changes are necessary for late stage
melanoma progression. A modi®cation of the same strategy
involved crossing the Ink4a±/±:Arf±/± mice with an ``inducible''
Tyr-Hras overexpresser mouse line (Chin et al, 2000), whereby
Hras expression could be repressed by the removal of a drug
(doxycycline) from the animals' feed. This downregulation resulted
in tumor regression in the animals that had already developed
melanomas, implicating Hras in tumor maintenance as well as
progression. This is an important ®nding, with obvious implica-
tions for treatment modalities targeting Ras in humans.
The question remained as to whether the functional knockout of
Ink4a or Arf was responsible for melanoma susceptibility in mice.
We now know that both genes are important. Two groups
(Krimpenfort et al, 2001; Sharpless et al, 2001) have generated
speci®c knockouts of the Ink4a gene in mice. Krimpenfort et al
introduced a stop signal at codon 101 in exon 2, which produced a
truncated, unstable Ink4a protein (termed Ink4a*/*), leaving Arf
unaffected. The other group, Sharpless et al, deleted exon 1a, also
leaving Arf expression unaffected. Although results from the two
groups vary somewhat (Table II), they are similar in that the
animals were prone to the development of various tumors, thus
con®rming Ink4a as a bona ®de tumor suppressor. These animals,
however, had a slightly lower frequency of spontaneous tumor
development than the Arf knockouts, but importantly, both strains
were susceptible to spontaneous melanoma development, albeit at
very low frequency. Carcinogen treatment had little effect on
melanoma incidence. The differences between the results of the
two studies may re¯ect differences in mouse strains or the strategies
for ablating Ink4a. Both studies transfected the Ink4a±/± MEFs with
Hras and found that they were resistant to transformation with the
oncogene, in contrast to MEFs from the Ink4a±/±:Arf±/± (Serrano
et al, 1996) and Arf±/± (Kamijo et al, 1997) mice, This indicates that,
at least in ®broblasts, Ras-induced transformation may be depend-
ent on abrogation of Arf function, together with the loss of Ink4a.
It is unclear how this may relate to melanoma development until
Ink4a±/±/Tyr-Hras and Arf±/±/Tyr-Hras mice are studied.
Intriguingly, in the study of Krimpenfort et al (2001), when the
Ink4a*/* mice were crossed with Arf hemizygotes, the animals
developed melanomas, the penetrance of which rose from 8% to
50% after treatment with DMBA. The effect of Arf haplo-
insuf®ciency in an Ink4a±/± background suggests cooperation
between the Ink4a and Arf pathways in melanoma development.
The notion of cross-talk between the two pathways has also been
suggested by Carnero et al (2000), who used anti-sense Ink4a and
Arf RNA constructs to study the effects of abrogation of both
pathways in MEFs. Their results were consistent with a model
where Arf normally regulates both the pRb and p53 pathways.
Recent work with mouse melanocytes cultured from
Ink4a±/±:Arf±/± mice suggests that Ink4a is necessary for senescence,
whereas Arf may be involved in cell death pathways (Sviderskaya et
al, 2002). In another study to assess the relative roles of these
pathways (Bardeesy et al, 2001), p53 knockout mice were mated
with Tyr-Hras transgenics, for direct comparison with
Ink4a±/±:Arf±/±:Tyr-Hras animals reported previously (Chin et al,
1997). p53±/±:Tyr-Hras mice also developed melanoma but with
lower penetrance (29% vs 60%). Melanoma cells were cultured
from the mouse tumors and Ink4a reintroduced by retroviral
delivery. As predicted, Ink4a did not suppress cell growth of the
p53±/±:Hras lines, whereas in cell lines derived from
Ink4a±/±:Arf±/±:Tyr-Hras mice, it ef®ciently inhibited cell growth.
Thus Ink4a is not involved in the p53/Ras-induced melanomas,
although this does not rule out a role for a compromised
downstream component in the Ink4a/cyclin D/Cdk4/pRb path-
way. These studies suggest that the Arf/p53 pathway can in¯uence
the activity of the Ink4a/pRb pathway in mouse melanocytes, but
not vice versa (Fig 3). ``Cross-talk'' between the two pathways
may be mediated at many levels. These may include E2F induction
of Arf transcription and direct binding of Arf to the E2F family of
transcription factors (Bates et al, 1998; Eymin et al, 2001), binding
of Mdm2 to pRb (Xiao et al, 1995), and p53 induction of p21Cip1,
which can inhibit the activity of Cdk4/cyclin D (reviewed in Chin
et al, 1998) and Cdk2/cyclin E (Mitra et al, 1999). Any of these
events are alternative mechanisms of pRb pathway inactivation that
may be capable of substituting for loss of Ink4a.
In summary, Cdkn2a may be involved in mouse melanoma
development through mechanisms involving both its Ink4a and Arf
transcripts. Hras, probably acting through Raf, is capable of
cooperating with the Arf/p53 pathway to initiate melanoma
development in mice, as is inactivation of Ink4a plus carcinogen
treatment and inactivation of Ink4a plus a decrease in physiologic
levels of Arf.
Cdk4 knockout/knockin mutants Further support for the role
of the Ink4a/cyclin D/Cdk4/pRb pathway in melanoma comes
from experiments with mice in which Cdk4 has been targeted by
homologous recombination to either ``knock out'' the gene, or to
``knock in'' the activating R24C mutation that is resistant to Ink4a
inhibition (Rane et al, 1999). Nullizygous Cdk4 animals were about
10% smaller than their wild-type littermates, with the females
infertile and males having defective spermatogenesis. The animals
also suffered from insulin-de®cient diabetes caused by defective
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pancreatic islet b cell development. On the other hand, the mice
expressing only R24C alleles were about 10% larger than their
littermates and developed hyperplasia of the endocrine pancreas,
but were otherwise normal. None of these animals developed
melanoma; however, they have shed further light on abrogation of
the pRb pathway(s) in tumorigenesis.
When the Cdk4R24C/R24C mice were studied over a longer time
frame (Sotillo et al, 2001a), it was found that endocrine tumors
were the second most common tumor type encountered
(hemangiosarcomas being the most frequent). These endocrine
tumors included pancreatic adenomas and pituitary carcinomas.
The appearance of pituitary tumors is reminiscent of the phenotype
of the Rb+/± (Jacks et al, 1992; Hu et al, 1994), Cdkn2c±/± (encoding
p18Ink4c), and Cdkn1b±/± (encoding p27Kip1) mice (Franklin et al,
1998), although these neoplasms generally appeared in the
adenohypophysis, not the pars intermedia as in the knockout
mouse models. Interestingly, p27Kip1 expression was nearly always
lost in the pituitary tumors from the Cdk4R24C/R24C mice. When
the Cdk4R24C/R24C and Cdkn1b±/± mice were crossed (Sotillo et al,
2001a), progeny with the compound mutant genotype developed
pituitary tumors with much decreased latency, and in this case the
tumors emanated from the pars intermedia. The role of p27Kip1 in
these tumors is unclear. In most tissues expression of the Ink4a-
resistant Cdk4 R24C increased Cdk4 but not Cdk2 kinase activity,
and did not induce a signi®cant redistribution of p27Kip1 to Cdk4/
cyclin D complexes. Thus, despite evidence that one of the
functions of Cdk4 is to sequester p27Kip1 and hence upregulate
Cdk2 activity (Sherr and Roberts, 1999), this does not seem to be
at play in these Cdk4 mutant mice. At least in the pituitary, there
appears to be a complex interplay between the Ink4a/cyclin D/
CDK4/pRb and p27/cyclin E/CDK2/pRb pathways that is not
understood.
Exposure of the Cdk4R24C/R24C mice to carcinogens (DMBA
and TPA) produced pigmented skin lesions that progressed to naevi
and CMM in 70% of animals (Sotillo et al, 2001b). Treatment with
DMBA alone produced CMM with decreased penetrance. The
Ink4a±/± animals discussed above (Krimpenfort et al, 2001; Sharpless
et al, 2001) were not treated with both DMBA and TPA, hence a
direct comparison is not possible. Activating Ras mutations were
associated with carcinogen-induced papillomas on the skin of both
wild-type and Cdk4R4C/R24C animals, but were rarely detected in
the melanocytic lesions from the animals expressing mutated Cdk4.
It has yet to be determined whether the carcinogen treatment
induces other mutations/epigenetic inactivation necessary for
melanoma formation, or whether additional mechanisms such as
suppression of the immune response or activation of other signaling
pathways are involved. To assess the role of various Ink4 inhibitors
in melanoma development, Sotillo et al (2001b) applied the same
DMBA/TPA carcinogen treatment to mice nullizygous for Cdkn2b
(encoding p15Ink4b), Cdkn2c (p18 Ink4c), and Ink4a/Arf. Increased
incidence of lymphomas resulting in death by 10±12 wk precluded
evaluation of skin lesions on Ink4a±/±:Arf±/± animals. Cdkn2b±/±
animals showed no increase in susceptibility to either papilloma or
melanoma, but the Cdkn1c±/± mice developed signi®cantly more
melanocytic lesions than wild-type controls. The tumors were
similar to those on the Cdk4R24C/R24C animals, but were less
aggressive. This indicates that p18Ink4c may play a part in
suppressing melanoma development in mice. This is unexpected,
as, no inactivating CDKN2C mutations have been detected in
human CMM (Platz et al, 1998). Untreated Cdkn2c±/± mice were
susceptible to adenomas of the pituitary and other tumors, but did
not develop melanoma (Franklin et al, 1998). These results suggest
that there must be a delicate balance of Cdk-inhibitor usage
dependent on cell type and environmental stimuli.
Figure 3. Pathways that may lead to cell cycle dysregulation in mouse melanocytes. The Ink4a/pRb and Arf/p53 pathways are depicted,
together with interactions that may represent cross-talk between the two pathways, which are described in the text. Also depicted are several mitogen-
activated Ras pathways that may affect cell cycle progression via upregulation of cyclin D, Cdk4, and/or cyclin E/Cdk2, which ultimately inactivate
pRb. Ras cooperates with Arf/p53 to induce melanoma development in mice by an unknown mechanism. These three growth regulation pathways
(Ink4a/pRb, Arf/p53, and Ras/MAPK) seem to represent three major ``axes'' of melanoma development in mice.
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Unlike those from Ink4a±/± animals, Cdk4R24C/R24C MEFs were
susceptible to transformation with activated Hras, but in contrast
with Ink4a±/±:Arf±/± MEFs, were not capable of producing tumors
in nude mice Moreover, the ``transformed'' Cdk4R24C/R24C clones
grew slower than even the nontransformed Ink4a±/±:Arf±/± MEFs,
further supporting the notion that defects in the Arf/p53 pathway
are more important for Ras transformation. Components of the
Arf/p53 pathway were intact in the melanomas from carcinogen-
treated mutant Cdk4 mice. Cdk4R24C/R24C:p53±/± mice, although
not treated with carcinogens, did not develop CMM (Sotillo et al,
2001a), indicating that inactivation of the p53 pathway cannot
substitute for carcinogen treatment. As in the Ink4a models,
however, this work recapitulates the model of melanoma suscep-
tibility in humans whereby an inherited mutation of CDKN2A or
CDK4 is followed by further environment-driven genetic ``hits''
throughout life.
Pten knockouts Homozygous knockout of Pten is embryonic
lethal in mice (Di Cristofano et al, 1998; Podsypanina et al, 1999),
and MEF derived from the embryos differentiate aberrantly. Pten+/±
mice develop hyperplastic/dysplastic changes in the prostate, skin,
and colon, closely resembling the human familial hamartoma
syndromes Cowden disease and Bannayan±Riley±Rivulcaba
syndrome, which are caused by defects in PTEN. These animals,
however, do not develop melanoma, or nervous system tumors,
suggesting that Pten is not involved in the development or
transformation of neural crest-derived cells. This notion is
challenged by results from a study by You et al (2002), who have
recently implicated Pten in mouse melanoma development. Their
study assessed the effects of Pten heterozygosity in an
Ink4a±/±:Arf±/± background by crossing the respective knockout
mice. Although the morphology and growth rates of MEFs from
Pten+/±:Ink4a±/±:Arf±/± mice were indistinguishable from
Ink4a±/±:Arf±/± MEFs, they were more susceptible to trans-
formation by activated Hras (increased number of large rapidly
growing foci). Interestingly, as well as the usual tumors seen in the
respective single gene knockouts, the compound knockout mice
developed a new spectrum of tumors, including invasive CMM and
squamous cell carcinoma. The authors postulated that the
melanoma development is due to the inactivation of Ink4a/Arf
together with activation of Ras (by loss of Pten suppression),
possibly analogous to that occurring in the mice reported by Chin
et al (1997), which also developed melanoma. This is supported by
genetic and functional studies on human PTEN (Tolkacheva and
Chan, 2000; Tsao et al, 2000), which indicate that both the PTEN/
Ras and p16/CDK4/pRb pathways need to be dysregulated for
melanoma development. As mentioned previously, Ras signaling is
also mediated though various effector pathways (Hunter, 1997),
including the Raf/MAPK, Ras/RalGDS, and Ras/PI3-K/Akt
pathways that regulate, among other things, cyclin D/CDK4
activity. Interestingly, a new role for PTEN may be the PI3K/
AKT-mediated regulation of cyclin E/CDK2 activity by
preventing ubiquitin-mediated degradation of p27Kip1 (Weng et
al, 2001). A similar function is also attributed to another Ras
effector, RhoA (Hu et al, 1999). This leads to a model for PTEN as
an inhibitor of CDK2 as well as CDK4 activity (Fig 3). Cdkn1b±/±
mice, do not develop prostate cancer, but yield a line of mice that
do so with complete penetrance when crossed with Pten+/± animals
(Di Cristofano et al, 2001), underlining the crucial role of Pten,
p27KIP1, and Cdk2 in malignant transformation, at least in prostatic
epithelial cells. To date, however, a direct role for CDK2
deregulation in human melanoma susceptibility has not been
indicated, as melanomas do not seem to harbor activating CDK2
mutations similar to those seen in CDK4 (Walker and Hayward,
2001), although at the protein level CDK2 is overexpressed in
some melanoma cell lines compared with normal melanocytes
(Tang et al, 1999).
Integration into an unknown locus An ``accidental''
melanoma model (Table II) was created by researchers seeking
to overexpress a genomic fragment (clone B) that caused adipoctyes
in culture to differentiate (Chen et al, 1996; Zhu et al, 1998). In one
of the ®ve founder lines generated, transgenic animals developed
metastatic CMM with complete penetrance. The primary lesions
were always initially detected in the skin of the ear or perianal
region, and appeared later on other parts of the body. Although
some transgenic mice developed OMM, these always derived from
uveal melanocytes in the choroid, not the RPE. The CMM began
as lesions resembling dysplastic naevi and progressed to invasive
melanomas. All skin lesions derived from melanocytes in the
dermis, not the hair follicles, indicating that there may be
something about the microenvironment in follicles that protects
melanocytes from transformation. The origin of these tumors
differs to that of human melanomas, which generally originate from
the basal layer of the epidermis, not the dermis. These mice are
intriguing, given the complete penetrance of CMM resulting from
the integration of clone B at an unknown location that may
inactivate a TSG, or activate an oncogene that is critically involved
in melanocyte homeostasis. This indicates that there may be other
strong genetic determinants of melanoma development yet to be
discovered.
ROLE OF UVR IN MOUSE MELANOMA
DEVELOPMENT
Experiments testing different protocols in terms of intensity,
timing, and duration of exposure have been used to assess the
role of UVR in CMM development in genetically engineered
mice. Tyr-SV40E mice developed melanoma with an increased
frequency and decreased latency compared with untreated animals
after exposure to UVR using several different treatment regimens
(Kelsall and Mintz, 1998). Studies using the high expresser
transgenic animals were impractical due to the very high mortality
rates from OMM. Using low susceptibility Tyr-SV40E lines,
however, Klein-Szanto et al (1994) and Kelsall and Mintz, 1998)
showed that melanocytic naevi and melanoma development could
best be promoted with a series of UVR treatments over 5 d
beginning at postnatal day 4. High intensity, but chronic exposures
to adult animals, however, have also been successful in inducing
CMM in Tyr-Hras mice, which do not generally develop this
neoplasm (Broome-Powell et al, 1999). Using a very similar
regimen (Table III), Kato et al (2000), reported that Mt1-Ret-
induced melanocytic tumors tended to become more invasive after
the animals were exposed to UVR.
The importance of treatment regimens was further underlined by
studies using the Mt-Hgf/Sf overexpresser mice. A UVR treatment
regimen exposing adult transgenics to long-term chronic doses
(Table III) had little effect on melanoma formation, but did
increase the frequency of nonmelanoma skin tumors (Noonan et al,
2000). When other protocols were employed, however, it was
discovered that with a single erythemal UVR dose to 3.5 d old
neonates, the frequency of CMM was dramatically increased, and
latency decreased, compared with the chronic dose to adult animals
(Noonan et al, 2001). The neonatal treatment was much more
effective at inducing CMM despite the total dose being 30-fold less
than that given to adult mice.
Surprisingly, UVR treatments on mice carrying mutations in the
human melanoma susceptibility genes (Ink4a±/±:Arf±/± and
Cdk4R24C/R24C) did not result in melanoma development
(Serrano et al, 1996; Sotillo et al, 2001b), despite use of an
experimental protocol consisting of neonatal exposure beginning as
early as postnatal day 4±8 in one of the studies (Serrano et al, 1996).
The Ink4a±/±:Arf±/±:Tyr-Hras animals were not exposed to UVR to
determine whether this had any effect on tumor latency or
penetrance.
Normal mice do not develop melanomas even when exposed to
chronic UVR treatments (Gallagher et al, 1984), so historically the
mouse has not been a good model for UVR-induced melanoma.
UV treatment protocols used on various genetically modi®ed mice
discussed here have been varied, but have generally used broad-
spectrum radiation consisting of 70±90% UVB, with a smaller
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portion of UVA to simulate solar UV light, which is a major risk
factor for melanoma development in humans. Generally, the most
successful protocols have used exposures that begin soon after birth,
at about day 4. This was successful for the transgenic lines
overexpressing SV40 Tag, and Hgf/Sf. It is puzzling, however, that
in the mouse models recapitulating the germline mutations in
human melanoma-prone families (Ink4±/±, Arf±/±, Cdk4R24C),
UVR treatments were unable induce CMM, despite neonatal
treatments of the Ink4±/±:Arf±/± animals. This could mean that
UVR-induced melanomas in mice may result from the degree of
``priming'' of melanocytes for transformation, by, for example, the
overactivity of SV40 Tag and Hgf/Sf during embryonic and
neonatal development. Arti®cial overexpression of these oncogenes
probably dysregulates multiple pathways and is more severe and
``unnatural'' than mutations of Cdkn2a or Cdk4, therefore making
melanocytes in the ``overexpresser'' transgenic mice more suscep-
tible to UV-induced transformation. The success of neonatal,
compared with chronic UVR exposure, however, ®ts nicely with
human epidemiologic studies where a high level of childhood sun
exposure is a strong determinant of melanoma risk (Whiteman et al,
2001). One explanation for this phenomenon in mice is that a
much higher proportion of melanocytes in neonates seem to be
located in the epidermal layer, whereas in adult mice melanocytes
are mainly localized to hair follicles, and thus possibly shielded to a
greater extent from UVR. Alternatively, it is known that
mammalian neonatal skin contains a higher proportion of
melanoblasts, and incompletely differentiated melanocytes, that
may be less well equipped to deal with UVR insults (Erickson,
1993) than melanocytes in adult skin.
CONCLUSIONS
By analysis of melanoma-prone families and sporadic tumors, the
involvement of several genes in human melanoma development has
been con®rmed. To date, the most important of these are
CDKN2A, CDK4, and PTEN. Studies analyzing the function of
these genes and their protein products are generally performed
in vitro where conclusions may often only represent one component
of activity and interactions within the intracellular milieu. Our
understanding of the molecular mechanisms of melanoma predis-
position, however, have been greatly improved by modeling
various pathways in the mouse. The Cdkn2a locus encodes two
totally different proteins, Ink4a and Arf. How the two apparently
distinct pathways, of which Ink4a and Arf are components,
cooperate to increase tumor susceptibility is puzzling, as there is
limited evidence for Arf involvement from genetic studies of
melanoma susceptibility and progression in humans. There is ample
evidence, however, of communication between the two pathways.
In addition, doubts about the importance of PTEN in melanoma
tumorigenesis have been quashed by the ®nding of cooperation
between the Ink4a/Arf and Pten pathways in mouse melanoma
development. We also know from mouse models that Ras pathway
activation is very important in melanoma development, either
through direct activation of Ras (e.g., Hras G12V), or via activation
of Ras-effector pathways by other oncogenes (e.g., Ret, Hgf/Sf).
From this information we can postulate models for melanoma
development that can be tested using various transgenic and
knockout mice. On the other hand, assuming that signals through
each pathway proceed in a linear manner may be too simplistic, and
ultimately, we may have to envisage a web of interacting pathways,
centered around pRb and p53, both of which may need to be
dysregulated for melanoma development. Finally, experiments with
genetically modi®ed mice have begun to give us some indications
of the intensity and timing of UV exposure that may be most
responsible for melanoma development. At ®rst glance, mice do
not appear to be a good model for melanoma as they do not
normally develop the neoplasm. But recent results using genetically
modi®ed animals have pointed melanoma researchers in some
unexpected directions.
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